The Center for Inquiry in Amherst is praising the recent Federal Trade Commission policy statement on the marketing of homeopathic drugs that they be held to the same advertising standards for scientific truthfulness as other products that claim health benefits.
Homeopathy is based on the view that disease symptoms can be treated by minute doses of substances that produce similar symptoms when provided in larger doses to healthy people.
“This is a real victory for reason, science, and the health of the American people,” Michael De Dora, public policy director for the Center for Inquiry, said in a statement. “The FTC has made the right decision to hold manufacturers accountable for the absolutely baseless assertions they make about homeopathic products.”
The Center filed comments last year urging the FTC to end false advertising of homeopathy, and De Dora testified before the Food and Drug Administration about the need to hold homeopathic drugs to the same standards of safety and efficacy as conventional medicine.